2012 Annual Report Medicines That Fuel Our Growth At Bristol-Myers Squibb, we rely on a  strong lineup of products to acceler- ate our growth and help fuel research  for promising future possibilities. Key  brands today include  Orencia  (abata- cept) for rheumatoid arthritis (RA);  Sprycel  (dasatinib) and  Erbitux  (cetux- imab) for cancer;  reyataz  (atazanavir),  Atripla  (efavirenz with emtricitabine  and tenofovir) and  Sustiva  (efavirenz)  for HIV/AIDS;  Baraclude  (enteca- vir) for hepatitis B; and  Onglyza (saxagliptin), and  Kombiglyze  XR and  Komboglyze  (saxagliptin and metfor- min HCl fixed-dose combinations) for  diabetes (also see pages 16-17). Not  only is use of many of these therapies  on the rise for approved indications,  but in many cases, new research is  seeking to examine their ability to  benefit more patients. Orencia  crossed $1 billion in annual  sales in 2012. Additional growth has  come with the approval of subcutane- ous (SC) administration in the U.S.,  Europe and Australia, allowing patients  who wish to do so to self-administer the  medication. Worldwide, SC formula- tions currently represent about 70 per- cent of the total RA biologics market,  80 percent in Europe alone. With its  unique mechanism of action, differ- ing from standard anti-tumor necrosis  factor (TNF) agents, and a balance of  efficacy and safety,  Orencia  provides  an important biologic alternative to stan- dard anti-TNF treatments. Also,  Orencia is the only biologic agent currently avail- able in both intravenous (IV) and SC  formulations for the treatment of RA. New clinical data from the  AMPLE study, presented last year, further  supports the efficacy of  Orencia . The  first large head-to-head trial of its kind  in RA,  AMPLE  found that  Orencia showed comparable efficacy to a com- monly prescribed TNF inhibitor. Further  exploring additional uses, Phase III  trials are beginning in lupus nephritis,  a complex disease with a high unmet  need, and in psoriatic arthritis.  (wild type) metastatic colorectal  cancer (mCRC) (about 60 percent of  the total mCRC population).  Erbitux was initially approved in 2004 as a  second-line or later treatment option  for mCRC. In 2011,  Erbitux  also  received approval as a first-line treat- ment option in recurrent metastatic  squamous cell carcinoma of the head  and neck. The new indications are  important advances in the treatment  of these two prevalent tumor types,  offering both prolonged survival and  increased response rates. Sprycel  became a billion-dollar prod- uct globally for the first time in 2012,  having established itself as an impor- tant medicine to treat chronic myeloid  leukemia (CML) in both treatment- naïve and refractory patients. Physi- cians appreciate the fast and deep  responses to the disease that  Sprycel offers and its ability to achieve early  response milestones. The approval  of  Sprycel  as a first-line therapy has  helped provide additional benefits  for patients newly diagnosed with  CML. Also, patients and physicians  increasingly value the demonstrated  long-term benefit and the simplicity of  Sprycel ’s once-daily dosing regimen.  Sprycel  was successfully launched  in China in mid-2012 for second-line  CML treatment, becoming our compa- ny’s first oncology therapy launched in  China in 17 years. To further address  areas of unmet medical need, ongo- ing studies are examining whether  CML patients who have significant  responses to  Sprycel  can eventually  come off therapy and maintain their  responses. Early studies also are  assessing  Sprycel  in mutation-defined  lung cancer and in pancreatic cancer.  In 2012,  Erbitux  was approved for  use as a first-line treatment option for  patients with KRAS-mutation-negative  Indeed, we have placed a special  focus on women living with HIV, a  vulnerable and growing population. In Europe, for example, where women  represent one-third of new HIV  diagnoses, the company, in partner- ship with an independent faculty that  includes health care providers and  patient groups, has launched SHE, an  A long-time leader in HIV treatments,  Bristol-Myers Squibb was the first  (partnering with Gilead) to bring a  single-tablet regimen to the market  with  Atripla . Despite an increasingly  competitive environment,  Atripla remains the number-one-prescribed  single tablet HIV regimen in the U.S., a  position built on a foundation of proven  efficacy and long-term virologic sup- pression.  reyataz , launched in 2003,  exhibits durable viral control and a  strong resistance profile. It is used in  both treatment-naïve and drug-resistant  patients and plays an important role  in the treatment of women, with data  supporting its efficacy and safety in this  population and with a unique label for  use in pregnant women with HIV/AIDS.  6 Bristol-Myers Squibb  Sprycel and Erbitux Reyataz , Atripla and Sustiva Orencia 